Strikingly, ATM is the only cell cycle checkpoint kinase gene enriched for mutation in the primary setting, as both CHEK2 (P = 0.001; Fig. 5B) and ATR mutations (P = 0.0002) are enriched in metastatic disease. This evidence concerns the gene ATM and metastatic neoplasm.